Sana Biotechnology マネジメント

マネジメント基準チェック /34

Sana Biotechnologyの CEO はSteve Harrで、 Sep2018年に任命され、の在任期間は 6.17年です。の年間総報酬は$ 2.67Mで、 24.7%給与と75.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.97%を直接所有しており、その価値は$ 22.41M 。経営陣と取締役会の平均在任期間はそれぞれ1.2年と5.3年です。

主要情報

Steve Harr

最高経営責任者

US$2.7m

報酬総額

CEO給与比率	24.7%
CEO在任期間	6.2yrs
CEOの所有権	4.0%
経営陣の平均在職期間	1.2yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

CEO報酬分析

Sana Biotechnology の収益と比較して、Steve Harr の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$306m
Jun 30 2024	n/a	n/a	-US$245m
Mar 31 2024	n/a	n/a	-US$309m
Dec 31 2023	US$3m	US$659k	-US$283m
Sep 30 2023	n/a	n/a	-US$276m
Jun 30 2023	n/a	n/a	-US$362m
Mar 31 2023	n/a	n/a	-US$320m
Dec 31 2022	US$4m	US$645k	-US$269m
Sep 30 2022	n/a	n/a	-US$300m
Jun 30 2022	n/a	n/a	-US$298m
Mar 31 2022	n/a	n/a	-US$207m
Dec 31 2021	US$1m	US$611k	-US$356m
Sep 30 2021	n/a	n/a	-US$358m
Jun 30 2021	n/a	n/a	-US$327m
Mar 31 2021	n/a	n/a	-US$433m
Dec 31 2020	US$7m	US$535k	-US$285m

報酬と市場: Steveの総報酬 ($USD 2.67M ) は、 US市場 ($USD 2.24M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Steveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Steve Harr (54 yo)

6.2yrs

在職期間

US$2,671,662

報酬

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Steven Harr	President	6.2yrs	US$2.67m	3.97% $ 22.4m
Susan Wyrick	Acting CFO	less than a year	データなし	0.066% $ 373.2k
Snehal Patel	Senior VP & Chief Technical Officer	less than a year	データなし	データなし
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	less than a year	データなし	データなし
Bernard Cassidy	Executive VP	2.2yrs	US$4.26m	0.042% $ 234.8k
Sonja Schrepfer	Senior VP & Head of Hypoimmune Platform	5.8yrs	データなし	データなし
Farah Anwar	Head of Development Operations	4yrs	データなし	データなし
Gary Meininger	Chief Medical Officer	1.6yrs	データなし	データなし
Yuko Soneoka	Head of Intellectual Property	less than a year	データなし	データなし
John Gerecitano	Head of Oncology Research & Development	less than a year	データなし	データなし

1.2yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: SANAの経営陣は経験豊富とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Steven Harr	President	6.1yrs	US$2.67m	3.97% $ 22.4m
Robert Taylor Nelsen	Independent Director	6.1yrs	US$294.80k	0.0062% $ 35.0k
Mary Wilderotter	Independent Director	4.5yrs	US$314.80k	0.0032% $ 18.0k
Douglas Cole	Independent Director	4.6yrs	US$302.30k	0.091% $ 511.9k
Patrick Yang	Independent Director	6.1yrs	US$299.80k	0.067% $ 377.6k
Michelle Seitz	Independent Director	4yrs	US$314.80k	0% $ 0
Richard Mulligan	Vice Chairman	6yrs	データなし	1.21% $ 6.8m
Hans Edgar Bishop	Independent Chairman of the Board	6.1yrs	US$354.80k	2.59% $ 14.6m
Joshua Bilenker	Independent Director	3.9yrs	US$299.80k	0.0090% $ 50.6k
Alise Reicin	Independent Director	3.9yrs	US$302.30k	0% $ 0

5.3yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: SANAの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Sana Biotechnology マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Independent Director recently sold US$236k worth of stock

Insufficient new directors

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-Cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index

Sana Biotechnology reports Q1 results

Sana Biotechnology to Present Pre-Clinical Data At American Society of Gene & Cell Therapy Annual Meeting 2021

Sana Biotechnology, Inc. has completed an IPO in the amount of $587.5 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /34